BAY 2927088 is an investigational oral, reversible TKI, designed to selectively target mutant forms of HER2 and EGFR, particularly in NSCLC harboring HER2-activating mutations (68). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.